EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Articles|February 27, 2017
Post-test: Nonmelanoma Skin Cancer for Primary Care
Author(s)Eve J. Lowenstein, MD, PhD
Find out what you've learned after reading this month's Special Report articles on nonmelanoma lesions you may see in primary care practice.
Advertisement
Question 1:
Click on links below for all sections of this Special Report, Non-melanoma Skin Cancer: A Primer for Primary Care
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
Advertisement
Advertisement
Trending on Patient Care Online
1
Primary Care Lens: Atrial Fibrillation From Detection to Referral in Primary Care
2
Menopause Care in Primary Care: Closing Diagnosis and Treatment Gaps
3
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
4
Elinzanetant for Menopause-Related VMS: Onset of Relief and Adverse Effects
5